StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a 12 month low of $0.53 and a 12 month high of $13.14. The stock has a 50 day moving average of $0.53 and a 200-day moving average of $1.48. The company has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.